Merck & Co., Inc. $MRK Shares Purchased by Triglav Investments D.O.O.

Triglav Investments D.O.O. increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 2.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 87,718 shares of the company’s stock after acquiring an additional 2,410 shares during the period. Triglav Investments D.O.O.’s holdings in Merck & Co., Inc. were worth $6,941,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Legend Financial Advisors Inc. acquired a new stake in Merck & Co., Inc. in the second quarter valued at $25,000. CBIZ Investment Advisory Services LLC grew its holdings in Merck & Co., Inc. by 141.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after purchasing an additional 221 shares during the last quarter. Advantage Trust Co grew its holdings in Merck & Co., Inc. by 57.1% in the second quarter. Advantage Trust Co now owns 550 shares of the company’s stock valued at $44,000 after purchasing an additional 200 shares during the last quarter. Chung Wu Investment Group LLC acquired a new stake in Merck & Co., Inc. in the second quarter valued at $45,000. Finally, MJT & Associates Financial Advisory Group Inc. acquired a new stake in Merck & Co., Inc. in the first quarter valued at $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $86.15 on Friday. The stock’s 50-day moving average is $84.57 and its 200-day moving average is $81.82. The company has a market cap of $215.17 billion, a price-to-earnings ratio of 13.27, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $105.07.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.22. The company had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period last year, the business posted $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on MRK shares. Citigroup started coverage on Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Morgan Stanley decreased their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.